Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4547 plus fulvestrant in ER+ breast cancer with FGFR1 amplification
NCT01202591Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2010
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of fexagratinib in estrogen receptor-positive breast cancer (ER+), sponsored by AstraZeneca. Started Dec 2010; status: completed.
02
Drugs
fexagratinib
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT01202591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01202591.